Evidence map›Paper›PMID 21243031›Full record

Trial reportBone marrow transplantation2011

Expression of CD64 (FcγRI) in skin of patients with acute GVHD.

A van Royen-Kerkhof, V Walraven, E A M Sanders, R de Weger, D F van Wichen, E de Koning, T Thepen, J G J van de Winkel, J H W Leusen

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

A van Royen-KerkhofImmunotherapy Laboratory, Department of Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
V Walraven
E A M Sanders
R de Weger
D F van Wichen
E de Koning
T Thepen
J G J van de Winkel
J H W Leusen
University Medical Center Utrecht · NLFraunhofer Institute for Molecular Biology and Applied Ecology · DEGenmab (Netherlands) · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

GVHD remains a major problem in allo-SCT. We explored the presence of APC in skin biopsies of GVHD patients, using the IgG receptor CD64 expression as a hallmark for activated APC. By immunohistochemistry we demonstrated CD64 to be upregulated on host APC in skin biopsies of patients with acute GVHD and, less prominently, in chronic GVHD. Double staining for CD32 polymorphism revealed CD64-positive cells to be mainly of host origin. The majority of CD64-positive cells coexpressed CD68, indicating a macrophage phenotype. Given its very restricted cellular distribution, CD64 may represent an excellent target for APC-directed therapies in GVHD.

Indexed as

Gene Expression RegulationAcute DiseaseAntigen-Presenting CellsChronic DiseaseFemaleGraft vs Host DiseaseHematologic NeoplasmsHumansMaleReceptors, IgGSkinSkin DiseasesStem Cell TransplantationTransplantation, HomologousReceptors, IgG

Identifiers

PMID21243031
OpenAlexW1515636265

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.